Arrhythmias & electrophysiology
Long-term health-related quality of life and rhythm outcomes of catheter ablation versus antiarrhythmic drugs in patients with atrial fibrillation
Authors' conclusion
HRQoL improvement in long-term did not differ between ablation and AAD groups despite a larger reduction in AF burden after ablation.
Study context
- Population
- Patients with symptomatic atrial fibrillation (AF)147 completed follow-up
- Participants
- 75 vs 74
- Comparison
- Catheter ablation vs AADs
- Ablationn = 75
- AADn = 74reference
- Primary endpoint
- General Health subscale of the SF-36
- Follow-up
- 48 months
Primary result
As reported in the abstract
SF-36 General Health
| Group | Value | Baseline | Change from baseline |
|---|---|---|---|
| Ablation | median 79.2 points | 62 | P < .001 |
| AAD | median 77 points | 67 | P < .001 |
Value
Ablationmedian 79.2 points
AADmedian 77 points
Baseline
Ablation62
AAD67
Change from baseline
AblationP < .001
AADP < .001
- Ablation vs AAD: P = 0.77 — no treatment difference
Further findings
Time to first AF episode ≥1 hour
P = 0.025
| Outcome | AblationMedian | AAD | P value |
|---|---|---|---|
| Cumulative AF burden during follow-up (implantable cardiac monitors) | 0.3% (IQR 0%–1.4%) | 1.6% (IQR 0.1%–11.0%) | P = 0.01 |
| Cumulative reduction in AF burden vs baseline | −89.5% (IQR −98.4%–-51.3%) | −52.7% (IQR −92.6%–263.6%) | P < 0.001 |
Original publication
Long-term health-related quality of life and rhythm outcomes of catheter ablation versus antiarrhythmic drugs in patients with atrial fibrillation. Heart Rhythm. Published 21 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →